Navitor Pharmaceuticals is a leading mTORC1 platform company that is revolutionizing targeted therapeutics. Their goal is to help patients increase their healthy years and enjoy uninterrupted quality of life. Navitor's innovative Navalog platform allows for precise modulation of mTORC1, which is the gatekeeper of cellular metabolism and renewal.

By addressing the underlying disease processes, Navitor's therapeutics have the potential to treat a wide range of conditions, from prevalent diseases like depression, heart failure, and chronic kidney disease to rare genetic disorders such as polycystic kidney disease and epilepsy. In collaboration with Supernus, Navitor is developing NV-5138, a sestrin ligand and mTORC1 activator for depression. Furthermore, Navitor's subsidiary, Anakuria Therapeutics, Inc., has been acquired by Janssen Pharmaceuticals, alongside their selective mTORC1 inhibitors.

With their cutting-edge research and commitment to improving patients' lives, Navitor Pharmaceuticals is at the forefront of medical innovation